Related Experiment Video

Updated: Jul 13, 2026

Spectral Confocal Imaging of Fluorescently tagged Nicotinic Receptors in Knock-in Mice with Chronic Nicotine Administration
08:47

Spectral Confocal Imaging of Fluorescently tagged Nicotinic Receptors in Knock-in Mice with Chronic Nicotine Administration

Published on: February 10, 2012

Rimonabant for treating tobacco dependence

Michael B Steinberg1, Jonathan Foulds

  • 1University of Medicine and Dentistry of New Jersey-School of Public Health, Tobacco Dependence Program, New Brunswick, NJ 08901, USA. michael.steinberg@umdnj.edu

Vascular Health and Risk Management
|August 21, 2007
PubMed

Insights

Rimonabant, a drug blocking cannabinoid receptors, shows potential for aiding smoking cessation and managing weight gain. However, inconsistent trial results mean its effectiveness for quitting tobacco use requires further investigation.

Area of Science:

  • Pharmacology
  • Addiction Medicine
  • Neuroscience

Background:

  • Tobacco use is a leading cause of preventable death globally, with low cessation rates despite available treatments.
  • Nicotine addiction involves complex physiological pathways, including the endocannabinoid system, offering targets for novel pharmacological interventions.
  • The endocannabinoid system, particularly cannabinoid receptor type 1, is implicated in nicotine reward pathways.

Purpose of the Study:

  • To evaluate the efficacy of rimonabant, a selective cannabinoid receptor type 1 blocker, as an aid for smoking cessation.
  • To assess the impact of rimonabant on weight gain in individuals attempting to quit smoking.
  • To determine the potential role of pharmacological agents targeting the endocannabinoid system in comprehensive tobacco cessation strategies.

Main Methods:

  • Early clinical trials investigated the effects of rimonabant in smokers attempting to quit.
  • Abstinence rates and weight changes were compared between groups receiving rimonabant and placebo.

Main Results:

  • Some early trials indicated that rimonabant may increase smoking abstinence rates.
  • Rimonabant use was associated with potentially less weight gain compared to placebo in some participants.
  • Results across available clinical trials have not been entirely consistent.

Conclusions:

  • Rimonabant demonstrates a potential role in enhancing smoking cessation and mitigating post-cessation weight gain.
  • The inconsistent findings across studies necessitate further research to definitively establish rimonabant's efficacy and safety as a smoking cessation aid.
  • Targeting the endocannabinoid system represents a promising avenue for developing new pharmacological treatments for nicotine dependence.

More Related Videos

Creating Dynamic Images of Short-lived Dopamine Fluctuations with lp-ntPET: Dopamine Movies of Cigarette Smoking14:21

Creating Dynamic Images of Short-lived Dopamine Fluctuations with lp-ntPET: Dopamine Movies of Cigarette Smoking

Published on: August 6, 2013

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Drug Dependence01:17

Drug Dependence

Medications are typically administered to achieve therapeutic effects. Some drugs can modify an individual's mood and perception, frequently resulting in various enjoyable experiences. However, this can result in drug dependency, a condition marked by continuous drug use despite potential negative consequences. Drug dependency primarily falls into two categories: psychological and physical dependence. Psychological dependence occurs when the pleasurable feelings induced by the drug...
CNS Depressants: Alcohol and Nicotine01:27

CNS Depressants: Alcohol and Nicotine

Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
Drugs Acting on Autonomic Ganglia: Stimulants01:23

Drugs Acting on Autonomic Ganglia: Stimulants


Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...